CN119300864A - 改善了低溶解性和/或低膜渗透性药物的吸收性的制剂 - Google Patents

改善了低溶解性和/或低膜渗透性药物的吸收性的制剂 Download PDF

Info

Publication number
CN119300864A
CN119300864A CN202380043670.9A CN202380043670A CN119300864A CN 119300864 A CN119300864 A CN 119300864A CN 202380043670 A CN202380043670 A CN 202380043670A CN 119300864 A CN119300864 A CN 119300864A
Authority
CN
China
Prior art keywords
low
drug
membrane
permeability
solubility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380043670.9A
Other languages
English (en)
Chinese (zh)
Inventor
中江崇
三轮泰司
滨本英利
辰巳升
山县丰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedRx Co Ltd
Original Assignee
MedRx Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedRx Co Ltd filed Critical MedRx Co Ltd
Publication of CN119300864A publication Critical patent/CN119300864A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380043670.9A 2022-03-31 2023-03-31 改善了低溶解性和/或低膜渗透性药物的吸收性的制剂 Pending CN119300864A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022060469 2022-03-31
JP2022-060469 2022-03-31
PCT/JP2023/013657 WO2023191082A1 (ja) 2022-03-31 2023-03-31 低溶解性および／または低膜透過性薬物の吸収性が改善された製剤

Publications (1)

Publication Number Publication Date
CN119300864A true CN119300864A (zh) 2025-01-10

Family

ID=88202476

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380043670.9A Pending CN119300864A (zh) 2022-03-31 2023-03-31 改善了低溶解性和/或低膜渗透性药物的吸收性的制剂

Country Status (5)

Country Link
US (1) US20250205339A1 (https=)
EP (1) EP4501358A4 (https=)
JP (1) JPWO2023191082A1 (https=)
CN (1) CN119300864A (https=)
WO (1) WO2023191082A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040028613A1 (en) * 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
AU2008327436B2 (en) * 2007-11-22 2013-09-05 Medrx Co., Ltd. External preparation composition comprising fatty acid-based ionic liquid as active ingredient
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
JP6482570B2 (ja) * 2014-10-30 2019-03-13 旭化成株式会社 経皮吸収促進剤及び経皮吸収促進助剤
BR112018008918A8 (pt) * 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
US11446253B2 (en) * 2017-11-17 2022-09-20 President And Fellows Of Harvard College Ionic liquids for internal delivery
AU2021241095A1 (en) * 2020-03-26 2022-10-27 Kyushu University, National University Corporation Ionic liquid, solvent, preparation, and transdermally absorbable agent

Also Published As

Publication number Publication date
US20250205339A1 (en) 2025-06-26
EP4501358A1 (en) 2025-02-05
JPWO2023191082A1 (https=) 2023-10-05
EP4501358A4 (en) 2026-03-25
WO2023191082A1 (ja) 2023-10-05

Similar Documents

Publication Publication Date Title
JP5566604B2 (ja) Ｐｕｆａ及び／又はウリジンを含有する組成物及びそれを使用した方法
JPWO2005060935A1 (ja) 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
WO2003068209A1 (en) Metformin salts of lipophilic acids
EP3261676B1 (en) Liquid levothyroxine formulations
Allam et al. Bioavailability: A pharmaceutical review
US7816373B2 (en) Method for improving adsorption of a drug from ethylene oxide derivative
WO2018113686A1 (zh) 水溶性富勒烯结构在制备治疗脂肪肝的药物中的应用
US20250032620A1 (en) Formulated and/or Co-Formulated Nanocarrier Compositions Containing TFGß Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof
CN119300864A (zh) 改善了低溶解性和/或低膜渗透性药物的吸收性的制剂
JP2018504392A (ja) 小分子を用いた鉄欠乏生物における生理機能の回復
JP6878309B2 (ja) 医薬組成物およびその使用
CN101584661A (zh) 一种供口服或静脉注射用索拉非尼自微乳化给药系统的制备及其应用
US20230226031A1 (en) Formulated and/or Co-Formulated Liposome Compositions Containing Immunogenic Cell Death (ICD) Inducing Prodrugs Useful In The Treatment of Cancer and Methods Thereof
CN112336731A (zh) 一种维生素口服液及其制备方法与应用
US20240287044A1 (en) Salt of selective fgfr4 inhibitor, and preparation method therefor and application thereof
JP2026501722A (ja) 微量元素組成物、その調製方法およびその使用
CN101495490B (zh) 含有多不饱和脂肪酸和/或尿苷的组合物及其使用方法
Vargas-Estrada et al. Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats
Isadiartuti et al. The pH-solubility profiles of levofloxacin hemihydrate and ciprofloxacin lactate
US20110189257A1 (en) Nanoparticle based therapy for aggregating mucin
CN102836124A (zh) 盐酸地巴唑滴眼液及其制备方法
CN104173288B (zh) 一种克拉霉素离子对脂质体注射液及其制备方法
CN120241604B (zh) 一种沃尼妙林长效复方制剂及其制备方法与应用
WO2022259958A1 (ja) リン脂質
CN109761915B (zh) 靶向mct1转运体的5-氟尿嘧啶成酯前药

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination